Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding

The crucial role of Myc as an oncoprotein and as a key regulator of cell growth makes it essential to understand the molecular basis of Myc function. The N-terminal region of c-Myc coordinates a wealth of protein interactions involved in transformation, differentiation and apoptosis. We have characterized in detail the intrinsically disordered properties of Myc-1–88, where hierarchical phosphorylation of S62 and T58 regulates activation and destruction of the Myc protein. By nuclear magnetic resonance (NMR) chemical shift analysis, relaxation measurements and NOE analysis, we show that although Myc occupies a very heterogeneous conformational space, we find transiently structured regions in residues 22–33 and in the Myc homology box I (MBI; residues 45–65); both these regions are conserved in other members of the Myc family. Binding of Bin1 to Myc-1–88 as assayed by NMR and surface plasmon resonance (SPR) revealed primary binding to the S62 region in a dynamically disordered and multivalent complex, accompanied by population shifts leading to altered intramolecular conformational dynamics. These findings expand the increasingly recognized concept of intrinsically disordered regions mediating transient interactions to Myc, a key transcriptional regulator of major medical importance, and have important implications for further understanding its multifaceted role in gene regulation.

[1]  V. Tompkins,et al.  Adenovirus E1A oncoprotein liberates c‐Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1‐dependent mechanism , 2008, Journal of cellular physiology.

[2]  M. Troxell,et al.  Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. , 2011, Cancer research.

[3]  Rebecca Page,et al.  Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors. , 2009, Journal of molecular biology.

[4]  Mike Tyers,et al.  Dynamic equilibrium engagement of a polyvalent ligand with a single-site receptor , 2008, Proceedings of the National Academy of Sciences.

[5]  T. Gibson,et al.  Protein disorder prediction: implications for structural proteomics. , 2003, Structure.

[6]  Roland L. Dunbrack,et al.  PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. , 2010, Biochimica et biophysica acta.

[7]  H. Chan,et al.  Polyelectrostatic interactions of disordered ligands suggest a physical basis for ultrasensitivity , 2007, Proceedings of the National Academy of Sciences.

[8]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[9]  R. Boelens,et al.  Altered flexibility in the substrate-binding site of related native and engineered high-alkaline Bacillus subtilisins. , 1999, Journal of molecular biology.

[10]  Wolfram Gronwald,et al.  Combined chemical shift changes and amino acid specific chemical shift mapping of protein–protein interactions , 2007, Journal of biomolecular NMR.

[11]  L. Penn,et al.  The myc oncogene: MarvelouslY Complex. , 2002, Advances in cancer research.

[12]  Toshiaki Hara,et al.  Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. , 2006, Molecular cell.

[13]  J. Momand,et al.  Solution conformation of an essential region of the p53 transactivation domain. , 1997, Folding & design.

[14]  J. Forman-Kay,et al.  NMR spectroscopy to study the dynamics and interactions of CFTR. , 2011, Methods in molecular biology.

[15]  J. Marsh,et al.  Sensitivity of secondary structure propensities to sequence differences between α‐ and γ‐synuclein: Implications for fibrillation , 2006 .

[16]  M. Kimmel,et al.  Conflict of interest statement. None declared. , 2010 .

[17]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[18]  J. Sedivy,et al.  Proteomic profiling of Myc-associated proteins , 2010, Cell cycle.

[19]  K. Wüthrich.  NMR of proteins and nucleic acids , 1988 .

[20]  J. Barrett,et al.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription , 1990, Molecular and cellular biology.

[21]  G. Prendergast,et al.  New Myc-interacting proteins: a second Myc network emerges , 1999, Oncogene.

[22]  D. Crouch,et al.  Suppression of MEK/ERK signalling by Myc: role of Bin-1. , 2005, Cellular signalling.

[23]  C. Dang.  Enigmatic MYC Conducts an Unfolding Systems Biology Symphony. , 2010, Genes & cancer.

[24]  L. Kay,et al.  Protein dynamics and conformational disorder in molecular recognition , 2009, Journal of molecular recognition : JMR.

[25]  M. Henriksson,et al.  Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation , 2009, Proceedings of the National Academy of Sciences.

[26]  A. Dunker,et al.  Predicting intrinsic disorder in proteins: an overview , 2009, Cell Research.

[27]  S. R. Hann.  Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. , 2006, Seminars in cancer biology.

[28]  L. Penn,et al.  Cancer therapeutics: targeting the dark side of Myc. , 2005, European journal of cancer.

[29]  L. J. Veer,et al.  TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[31]  H. Dyson,et al.  Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.

[32]  K. Nakayama,et al.  Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7 , 2004, The EMBO journal.

[33]  R. Burton,et al.  B-myc: N-terminal recognition of myc binding proteins. , 2006, Biochemistry.

[34]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[35]  References , 1971 .

[36]  Francesca Massi,et al.  Characterization of the dynamics of biomacromolecules using rotating-frame spin relaxation NMR spectroscopy. , 2006, Chemical reviews.

[37]  Lorna J. Smith,et al.  Long-Range Interactions Within a Nonnative Protein , 2002, Science.

[38]  L. Kay,et al.  An NMR experiment for the accurate measurement of heteronuclear spin-lock relaxation rates. , 2002, Journal of the American Chemical Society.

[39]  Julie D. Forman-Kay,et al.  Structural signature of the MYPT1-PP1 interaction. , 2011, Journal of the American Chemical Society.

[40]  Ernest Martinez,et al.  Dual Regulation of c-Myc by p300 via Acetylation-Dependent Control of Myc Protein Turnover and Coactivation of Myc-Induced Transcription , 2005, Molecular and Cellular Biology.

[41]  Lixiao Wang,et al.  OnD-CRF: predicting order and disorder in proteins conditional random fields , 2008, Bioinform..

[42]  C. Arrowsmith,et al.  p53 Transcriptional Activation Domain: A Molecular Chameleon? , 2006, Cell cycle.

[43]  K. Dahlman-Wright,et al.  Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding. , 1996, Biochemistry.

[44]  Chong Li,et al.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.

[45]  B. Lüscher,et al.  The Ins and Outs of MYC Regulation by Posttranslational Mechanisms* , 2006, Journal of Biological Chemistry.

[46]  P. Knoepfler,et al.  Acting locally and globally: Myc's ever-expanding roles on chromatin. , 2009, Cancer research.

[47]  H. Varmus,et al.  Definition of regions in human c-myc that are involved in transformation and nuclear localization , 1987, Molecular and cellular biology.

[48]  Kyou-Hoon Han,et al.  Local Structural Elements in the Mostly Unstructured Transcriptional Activation Domain of Human p53* , 2000, The Journal of Biological Chemistry.

[49]  M. Cole,et al.  Mechanism of transcriptional activation by the Myc oncoproteins. , 2006, Seminars in cancer biology.

[50]  G. Prendergast,et al.  Bin1 mediates apoptosis by c-Myc in transformed primary cells. , 2001, Cancer research.

[51]  Peter E Wright,et al.  Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. , 2010, Biochemistry.

[52]  Joseph R. Nevins,et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.

[53]  Robert Wechsler-Reya,et al.  BIN1 is a novel MYC–interacting protein with features of a tumour suppressor , 1996, Nature Genetics.

[54]  Michael D. Cole,et al.  Transcription-independent functions of MYC: regulation of translation and DNA replication , 2008, Nature Reviews Molecular Cell Biology.

[55]  G. Prendergast,et al.  Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma , 2000, International journal of cancer.

[56]  L. Penn,et al.  More than MAX: Discovering the Myc interactome , 2011, Cell cycle.

[57]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[58]  Chong Li,et al.  D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms , 2010, Proceedings of the National Academy of Sciences.

[59]  Stuart H. Orkin,et al.  A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs , 2010, Cell.

[60]  J. Forman-Kay,et al.  CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices , 2007, Nature Structural &Molecular Biology.

[61]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[62]  Thomas Szyperski,et al.  A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. , 2005, Journal of molecular biology.

[63]  B. Persson,et al.  BRICHOS - a superfamily of multidomain proteins with diverse functions , 2009, BMC Research Notes.

[64]  I. Magrath,et al.  Point mutations in the c–Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas , 1993, Nature Genetics.

[65]  Maria Sunnerhagen,et al.  N and C-terminal sub-regions in the c-Myc transactivation region and their joint role in creating versatility in folding and binding. , 2005, Journal of molecular biology.

[66]  C. Dang,et al.  Definition of the activities and properties of c-myc required to inhibit cell differentiation. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[67]  Zsuzsanna Dosztányi,et al.  ANCHOR: web server for predicting protein binding regions in disordered proteins , 2009, Bioinform..

[68]  C. Hawkins,et al.  Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. , 2005, Cancer Research.

[69]  Baoli Hu,et al.  Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. , 2007, Cancer research.

[70]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[71]  B. Clurman,et al.  FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation , 2008, Nature Reviews Cancer.

[72]  M. Cole,et al.  The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.

[73]  Cheryl H. Arrowsmith,et al.  A novel strategy for NMR resonance assignment and protein structure determination , 2011, Journal of biomolecular NMR.

[74]  L. Larsson,et al.  c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. , 2000, Blood.

[75]  C. Arrowsmith,et al.  Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Colin J. Daniel,et al.  The Axin1 scaffold protein promotes formation of a degradation complex for c‐Myc , 2009, The EMBO journal.

[77]  John W. Tukey,et al.  Data Analysis and Regression: A Second Course in Statistics , 1977 .

[78]  Wei Du,et al.  Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms , 1999, Oncogene.

[79]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[80]  T. Pawson,et al.  Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. , 1994, Biochemistry.

[81]  Maria Miller,et al.  Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. , 2009, Structure.